Form 4: Teladoc Health Exec Sells Shares for Tax Obligations

Teladoc Health's President, International, Carlos Nueno, reported the acquisition of shares from vested equity awards and a subsequent sale to cover tax withholding obligations.

Summary

• Carlos Nueno, President, International of Teladoc Health, Inc. (TDOC), reported transactions on December 1 and December 2, 2025.
• On December 1, 2025, Nueno acquired 1,056 shares of common stock from the conversion of performance stock units.
• Also on December 1, 2025, Nueno acquired 3,101 shares and 4,556 shares of common stock from the conversion of restricted stock units.
• On December 2, 2025, Nueno sold 3,897 shares of common stock at a price of $7.488 per share.
• The sale was conducted to cover tax withholding obligations related to the vesting of his performance stock unit and restricted stock unit awards.
• Following these transactions, Nueno beneficially owns 27,175 shares of Teladoc Health common stock directly.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to equity compensation vesting and tax obligations. The executive continues to hold a substantial number of shares, indicating ongoing alignment. The sale is non-discretionary for tax purposes, so it doesn't signal a lack of confidence.

Positives

• Vesting of performance and restricted stock units indicates the achievement of performance milestones or continued employment, reflecting positively on the executive's tenure and potentially company performance.
• The executive continues to hold a significant number of shares (27,175), indicating ongoing alignment with shareholder interests.

Negatives

• The sale of shares, even for tax purposes, reduces the executive's direct ownership stake in the company.

Future Outlook

The filing details future vesting schedules for performance and restricted stock units, indicating ongoing equity compensation for the executive. Specifically, the remaining portions of 12,679 performance stock units and 37,202 restricted stock units will vest in eight substantially equal quarterly installments after March 1, 2024. Additionally, the remaining portion of 54,675 restricted stock units will vest in eight substantially equal quarterly installments beginning June 1, 2025, after the initial one-third vesting on the first anniversary of the March 19, 2024 grant date.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions related to equity compensation and tax obligations. It does not provide information directly related to broader industry trends or competitive landscape. However, the continued use of performance and restricted stock units is a common practice in the technology and healthcare sectors to incentivize and retain key executives.

Comparison to Industry Standards

• The transactions reported are standard for executive compensation plans in publicly traded companies, particularly the vesting of equity awards and subsequent "sell-to-cover" transactions for tax purposes.
• This practice is widely adopted across various industries, including healthcare technology, to manage the tax implications of equity-based compensation.
• No specific comparable companies or projects are mentioned in the filing.

Related Party Transactions

• The transactions themselves are related party transactions, as they involve an executive of the company acquiring and disposing of company stock.
• The acquisition of shares through vesting of performance and restricted stock units is part of the executive's compensation package.
• The sale of shares to cover tax withholding obligations is a direct consequence of this compensation.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even for tax purposes, slightly increases the float and could be perceived neutrally or slightly negatively if not understood as a tax-related event. The continued holding of a significant stake by the executive aligns interests.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of equity compensation and subsequent sales to cover tax obligations. Such transactions are common and generally non-discretionary, thus they typically do not signal a change in the executive's confidence in the company's future prospects. The executive retains a substantial holding, maintaining alignment with shareholder interests. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation; a "hold" stance is appropriate as it reflects the lack of significant new positive or negative catalysts from this report.

Keywords

Teladoc Health, TDOC, Carlos Nueno, Form 4, Insider Trading, Stock Units, Restricted Stock Units, Performance Stock Units, Equity Compensation, Tax Withholding, Share Sale